Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.48 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23151040 | 1.00 | PLA2G2A (0.48) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL21552430 | 1.00 | PLA2G2A (0.48) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL21552676 | 1.00 | PLA2G2A (0.48) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL21552605 | 1.00 | PLA2G2A (0.48) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL21552582 | 1.00 | PLA2G2A (0.48) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL31691183 | 0.99 | PLA2G2A (0.45) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL21523095 | 0.99 | PLA2G2A (0.45) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL23150907 | 0.94 | MEN1 (0.40) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL23150912 | 0.87 | MEN1 (0.34) | PLA2G2APLA2G5FFAR1MEN1KMT2A | |
| SCHEMBL23150915 | 0.76 | FAAH (0.41) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166603-A1 | Method of Treating Cancer With Atpenin A5 Derviatives | UNIV TEXAS TECH SYSTEM (US) | 2024-05-23 | — | — | US | disclosed |
| US-20210093617-A1 | Method of Treating Cancer With Atpenin A5 Derviatives | UNIVERSITY OF ROCHESTER MEDICAL CENTER | 2021-04-01 | — | — | US | disclosed |
| WO-2019217631-A1 | METHOD OF TREATING CANCER WITH ATPENIN A5 DERVIATIVES | TEXAS TECH UNIVERSITY SYSTEM (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093617-A1 | Method of Treating Cancer With Atpenin A5 Derviatives | ATP5ME, ANXA5, ATP5MG | PLA2G2A 215/4885PLA2G5 87/4885FFAR1 1346/4885 |
| US-20240166603-A1 | Method of Treating Cancer With Atpenin A5 Derviatives | ATP5MG, ATP5ME, ATP5MK | PLA2G2A 688/4885PLA2G5 98/4885FFAR1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.